FDA grants Orphan Drug Designation to CERo's CER-1236 for AML treatment

CERO THERAPEUTICS HOLDINGS, INC.

FDA Orphan Drug Designation granted to CER-1236 for acute myeloid leukemia (AML).
CER-1236 is an engineered T cell therapy leveraging phagocytic mechanisms; currently in Phase 1 trial.
ODD qualifies CERo for 7-year marketing exclusivity, FDA trial assistance, and fee exemptions.
AML is a life-threatening condition affecting ≤200,000 US patients annually.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.